Cardiol Therapeutics Class Stock Net Income
| CRDL Stock | USD 1.36 0.07 4.90% |
Cardiol Therapeutics Class fundamentals help investors to digest information that contributes to Cardiol Therapeutics' financial success or failures. It also enables traders to predict the movement of Cardiol Stock. The fundamental analysis module provides a way to measure Cardiol Therapeutics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Cardiol Therapeutics stock.
| Last Reported | Projected for Next Year | ||
| Net Loss | -28 M | -29.4 M | |
| Net Loss | -27.8 M | -29.2 M | |
| Net Loss | -28.1 K | -29.5 K | |
| Net Loss | (0.44) | (0.46) | |
| Net Income Per E B T | 0.43 | 0.41 |
Cardiol | Net Income |
Cardiol Therapeutics Class Company Net Income Analysis
Cardiol Therapeutics' Net income is the profit of a company for the reporting period, which is derived after taking revenues and gains and subtracting all expenses and losses. Net income is one of the most-watched numbers by money managers as well as individual investors.
Current Cardiol Therapeutics Net Income | (28.13 K) |
Most of Cardiol Therapeutics' fundamental indicators, such as Net Income, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Cardiol Therapeutics Class is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Cardiol Net Income Driver Correlations
Understanding the fundamental principles of building solid financial models for Cardiol Therapeutics is extremely important. It helps to project a fair market value of Cardiol Stock properly, considering its historical fundamentals such as Net Income. Since Cardiol Therapeutics' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Cardiol Therapeutics' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Cardiol Therapeutics' interrelated accounts and indicators.
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
| Competition |
Cardiol Accumulated Other Comprehensive Income
Accumulated Other Comprehensive Income |
|
Based on the recorded statements, Cardiol Therapeutics Class reported net income of (28,128). This is 100.01% lower than that of the Biotechnology sector and significantly lower than that of the Health Care industry. The net income for all United States stocks is 100.0% higher than that of the company.
Cardiol Net Income Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Cardiol Therapeutics' direct or indirect competition against its Net Income to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Cardiol Therapeutics could also be used in its relative valuation, which is a method of valuing Cardiol Therapeutics by comparing valuation metrics of similar companies.Cardiol Therapeutics is currently under evaluation in net income category among its peers.
Cardiol Therapeutics Current Valuation Drivers
We derive many important indicators used in calculating different scores of Cardiol Therapeutics from analyzing Cardiol Therapeutics' financial statements. These drivers represent accounts that assess Cardiol Therapeutics' ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Cardiol Therapeutics' important valuation drivers and their relationship over time.
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Market Cap | 118.3M | 83.0M | 100.7M | 43.1M | 49.6M | 93.1M | |
| Enterprise Value | 111.5M | 69.1M | 16.9M | (16.3M) | (18.7M) | (17.8M) |
Cardiol Therapeutics Institutional Holders
Institutional Holdings refers to the ownership stake in Cardiol Therapeutics that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Cardiol Therapeutics' outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Cardiol Therapeutics' value.| Shares | Bank Of Montreal | 2024-09-30 | 50 K | Bmo Capital Markets Corp. | 2024-09-30 | 50 K | Marble Harbor Investment Counsel, Llc | 2024-09-30 | 36.9 K | Goldman Sachs Group Inc | 2024-09-30 | 36.1 K | Sontag Advisory Llc | 2024-09-30 | 30.3 K | Susquehanna International Group, Llp | 2024-09-30 | 25.3 K | Group One Trading, Lp | 2024-09-30 | 24.8 K | Two Sigma Investments Llc | 2024-09-30 | 24.7 K | Royal Bank Of Canada | 2024-09-30 | 24.1 K | Tejara Capital Ltd | 2024-09-30 | 1.8 M | Advisorshares Investments, Llc | 2024-09-30 | 1.2 M |
Cardiol Fundamentals
| Return On Equity | -1.08 | ||||
| Return On Asset | -0.54 | ||||
| Current Valuation | 105.77 M | ||||
| Shares Outstanding | 81.6 M | ||||
| Shares Owned By Insiders | 3.91 % | ||||
| Shares Owned By Institutions | 9.50 % | ||||
| Number Of Shares Shorted | 1.13 M | ||||
| Price To Book | 15.86 X | ||||
| Price To Sales | 1,069 X | ||||
| Gross Profit | 78.76 K | ||||
| EBITDA | (29.59 M) | ||||
| Net Income | (28.13 K) | ||||
| Cash And Equivalents | 70.45 M | ||||
| Cash Per Share | 1.14 X | ||||
| Total Debt | 174.34 K | ||||
| Debt To Equity | 0 % | ||||
| Current Ratio | 6.48 X | ||||
| Book Value Per Share | 0.43 X | ||||
| Cash Flow From Operations | (25.18 K) | ||||
| Short Ratio | 1.37 X | ||||
| Earnings Per Share | (0.38) X | ||||
| Target Price | 8.79 | ||||
| Beta | 0.7 | ||||
| Market Capitalization | 116.86 M | ||||
| Total Asset | 36.7 M | ||||
| Retained Earnings | (142.58 M) | ||||
| Working Capital | 51.63 M | ||||
| Net Asset | 36.7 M |
About Cardiol Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Cardiol Therapeutics Class's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Cardiol Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Cardiol Therapeutics Class based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Cardiol Therapeutics Piotroski F Score and Cardiol Therapeutics Altman Z Score analysis. You can also try the Efficient Frontier module to plot and analyze your portfolio and positions against risk-return landscape of the market..
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Cardiol Therapeutics. If investors know Cardiol will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Cardiol Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.38) | Return On Assets (0.54) | Return On Equity (1.08) |
The market value of Cardiol Therapeutics is measured differently than its book value, which is the value of Cardiol that is recorded on the company's balance sheet. Investors also form their own opinion of Cardiol Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Cardiol Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Cardiol Therapeutics' market value can be influenced by many factors that don't directly affect Cardiol Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Cardiol Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Cardiol Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Cardiol Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.